Previous 10 | Next 10 |
NOVATO, Calif., May 11, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced that Shalini Sharp, the company's Chief Financial Office...
The following slide deck was published by Ultragenyx Pharmaceutical Inc. in conjunction with their 2020 Q1 earnings Read more ...
Image source: The Motley Fool. Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) Q1 2020 Earnings Call May 6, 2020 , 5:00 p.m. ET Operator Continue reading
Ultragenyx Pharmaceutical Inc. (RARE) Q1 2020 Earnings Conference Call May 06, 2020, 05:00 PM ET Company Participants Danielle Keatley - Senior Director of IR Emil Kakkis - CEO and President Shalini Sharp - CFO Camille Bedrosian - Chief Medical Officer Erik Harris - Chief Com...
Ultragenyx Pharmaceutical (NASDAQ: RARE ): Q1 GAAP EPS of -$2.05 misses by $0.37 . More news on: Ultragenyx Pharmaceutical Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
First quarter 2020 total revenue is $36.3 million First quarter 2020 Crysvita revenue in Ultragenyx territories is $28.8 million Maintains full year 2020 guidance based on COVID-19 impact to date NOVATO, Calif., May 06, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (N...
SARASOTA, Fla. and NOVATO, Calif., May 04, 2020 (GLOBE NEWSWIRE) -- GeneTx Biotherapeutics LLC and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare diseases, today an...
NOVATO, Calif., April 30, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call on Wednesday, May ...
NOVATO, Calif., April 28, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for rare and ultra-rare diseases, today announced that clinical, preclinical and manufacturin...
Source : ClearBridge Investments Editor's Note : The summary bullets for this article were chosen by Read more ...
News, Short Squeeze, Breakout and More Instantly...
Ultragenyx Pharmaceutical Inc. Company Name:
RARE Stock Symbol:
NASDAQ Market:
Ultragenyx Pharmaceutical Inc. Website:
NOVATO, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultrarare genetic diseases, today announced that it will host a conference call at 5...
NOVATO, Calif., July 24, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the company will share the latest clinical data, regulatory progress and program next steps for GTX-102, its investigational antisense oligonucleotide for Angelman syndrome, on Wed...
2024-07-24 04:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...